BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 9586122)

  • 21. Ribozyme-catalyzed tRNA aminoacylation.
    Lee N; Bessho Y; Wei K; Szostak JW; Suga H
    Nat Struct Biol; 2000 Jan; 7(1):28-33. PubMed ID: 10625423
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Satellite cereal yellow dwarf virus-RPV (satRPV) RNA requires a douXble hammerhead for self-cleavage and an alternative structure for replication.
    Song SI; Silver SL; Aulik MA; Rasochova L; Mohan BR; Miller WA
    J Mol Biol; 1999 Nov; 293(4):781-93. PubMed ID: 10543967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The effect of anti-bcr-abl hammerhead ribozyme on bone marrow purging].
    Wu Y; Chen YZ; Huang HF; Chen P; Lu LH
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Sep; 35(9):859-63. PubMed ID: 12958661
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A cis and trans adenine-dependent hairpin ribozyme against Tpl-2 target.
    Li YL; Torchet C; Vergne J; Maurel MC
    Biochimie; 2007 Oct; 89(10):1257-63. PubMed ID: 17703868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design and kinetic analysis of hammerhead ribozyme and DNAzyme that specifically cleave TEL-AML1 chimeric mRNA.
    Choi WH; Choi BR; Kim JH; Yeo WS; Oh S; Kim DE
    Biochem Biophys Res Commun; 2008 Sep; 374(1):169-74. PubMed ID: 18627769
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Catalytic activity of hammerhead ribozymes in a clay mineral environment: implications for the RNA world.
    Biondi E; Branciamore S; Fusi L; Gago S; Gallori E
    Gene; 2007 Mar; 389(1):10-8. PubMed ID: 17125938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Engineered RNase P ribozymes inhibit gene expression and growth of cytomegalovirus by increasing rate of cleavage and substrate binding.
    Trang P; Hsu A; Zhou T; Lee J; Kilani AF; Nepomuceno E; Liu F
    J Mol Biol; 2002 Jan; 315(4):573-86. PubMed ID: 11812131
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selection of hammerhead ribozyme variants with low Mg2+ requirement: importance of stem-loop II.
    Persson T; Hartmann RK; Eckstein F
    Chembiochem; 2002 Nov; 3(11):1066-71. PubMed ID: 12404631
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The 5'-end of hTERT mRNA is a good target for hammerhead ribozyme to suppress telomerase activity.
    Yokoyama Y; Takahashi Y; Shinohara A; Wan X; Takahashi S; Niwa K; Tamaya T
    Biochem Biophys Res Commun; 2000 Jun; 273(1):316-21. PubMed ID: 10873604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determination of hammerhead ribozyme kinetic constants at high molar ratio ribozyme-substrate.
    Grassi G; Grassi M; Kuhn A; Kandolf R
    J Math Biol; 2002 Sep; 45(3):261-77. PubMed ID: 12373347
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Developing RNase P ribozymes for gene-targeting and antiviral therapy.
    Trang P; Kim K; Liu F
    Cell Microbiol; 2004 Jun; 6(6):499-508. PubMed ID: 15104592
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Designer ribozymes: programming the tRNA specificity into flexizyme.
    Ramaswamy K; Saito H; Murakami H; Shiba K; Suga H
    J Am Chem Soc; 2004 Sep; 126(37):11454-5. PubMed ID: 15366888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficient hammerhead ribozyme and antisense RNA targeting in a slow ribosome Escherichia coli mutant.
    Chen H; Ferbeyre G; Cedergren R
    Nat Biotechnol; 1997 May; 15(5):432-5. PubMed ID: 9131620
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Highly active low magnesium hammerhead ribozyme.
    Fedoruk-Wyszomirska A; SzymaƄski M; Wyszko E; Barciszewska MZ; Barciszewski J
    J Biochem; 2009 Apr; 145(4):451-9. PubMed ID: 19124457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activity of minimised hammerhead ribozymes.
    Hendry P; McCall MJ; Santiago FS; Jennings PA
    Nucleic Acids Res; 1995 Oct; 23(19):3922-7. PubMed ID: 7479037
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulation of ribozyme cleavage activity by oligonucleotides.
    Komatsu Y; Ohtsuka E
    Methods Mol Biol; 2004; 252():165-77. PubMed ID: 15017048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro evolution of the hammerhead ribozyme to a purine-specific ribozyme using mutagenic PCR with two nucleotide analogues.
    Kore AR; Vaish NK; Morris JA; Eckstein F
    J Mol Biol; 2000 Sep; 301(5):1113-21. PubMed ID: 10966809
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The tolerance to exchanges of the Watson Crick base pair in the hammerhead ribozyme core is determined by surrounding elements.
    Przybilski R; Hammann C
    RNA; 2007 Oct; 13(10):1625-30. PubMed ID: 17666711
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Attenuation of telomerase activity by hammerhead ribozymes targeting human telomerase RNA and telomerase reverse transcriptase in pancreatic carcinoma cells.
    Hayashidani Y; Hiyama E; Murakami Y; Sueda T
    Hiroshima J Med Sci; 2005 Mar; 54(1):21-7. PubMed ID: 15847061
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Probing of the secondary structure of maxizymes.
    Zhou JM; Nakamatsu Y; Kuwabara T; Warashina M; Tanaka Y; Yoshinari K; Taira K
    Nucleic Acids Symp Ser; 1999; (42):219-20. PubMed ID: 10780458
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.